Top 10 Deals of 2025: Hinge Health IPOs, Breaking the Stalemate

This week we unpack one of the first major IPOs in digital health, Hinge Health’s debut.

Hinge Health, a San Francisco-based musculoskeletal (MSK) care service provider, went public on the NYSE in May 2025. The company posted $390 million in revenue for the year 2024 and currently sits at a $3.9B Enterprise Value. Investors include Insight, Tiger Global, and Bessemer Venture Partners.

Women face MSK disorders at ~50% higher rates than men, with the gap widening with age, affecting quality of life, independence, and economic productivity (source). While we don’t have access to Hinge Health’s patient demographic data, we would bet that the majority are women. As MSK disorders disproportionately affect women, we claim Hinge Health in the women’s health vertical.    

If public investors reward scaled virtual-care platforms with strong outcomes and predictable reimbursement, we expect capital to flow toward women’s health models that do the same. In short: Hinge Health’s reception won’t just shape MSK comps; it could reset the bar and unlock momentum for the broader women’s health category.

Hinge, founded in 2014, delivers a virtual MSK clinic that lets patients manage acute injuries, chronic pain, and post-operative rehab through app-based exercise therapy, tele-PT, coaching, and motion-sensor-guided programs. The platform integrates with care navigation and claims data to identify eligible members, streamline onboarding, and produce ROI reporting—supporting renewals and expansion into adjacent pathways (pre-/post-op, spine, shoulder, knee, pelvic floor). Hinge sells to large self-insured employers and health plans, typically using a per-employee-per-month structure complemented by case-based fees and outcomes guarantees.

‍

This burden is especially acute in women’s health: more than 70% of women experience MSK symptoms from perimenopause through post menopause, and roughly 25% become disabled by these issues—numbers that underscore both the severity of untreated conditions and the limits of current care (source).

That’s precisely where scaled virtual MSK models matter: evidence-based programs delivered through employers and health plans. By meeting women earlier, across prevention, peri-/post-operative care, pelvic floor, and menopause-related pathways, the system can extend not just longevity but health-span.

Innovation in MSK care is necessary to close access gaps for women. We’re already seeing a number of early-stage players rise to meet this need.

Examples of emerging innovation:

  • Origin (Amboy Street portfolio company; Series B) — In person and virtual pelvic floor physical therapy care for pregnancy, postpartum, menopause, and sexual health.

‍

  • Commons Clinic (Series A) — In-person and virtual wholebody specialty care from advanced orthopedics to whole body preventative health including women’s health, cardiology and weight loss.

‍

  • Sword Health (Series E) — Virtual solutions for muscle and joint pain, pelvic health conditions, movement health, and mental health.

‍

With a growing market and persistent challenges in MSK care, innovations like these will be key to improving patient outcomes.

Continue Reading

Top 10 Deals of 2026: ŌURA to Acquire Counsel Health for $625M

Every year, Amboy Street highlights the top 10 transactions in women’s health. The next deal in this year’s series is ŌURA’s agreement to acquire Counsel Health, an AI-native primary care company, for $625 million in cash.

Top 10 Deals of 2026: Ferring to Acquire Gameto for up to $1.38B

Every year, Amboy Street highlights the top 10 transactions in women’s health. The splashy news of the week, and the next blog in our series, is Ferring Pharmaceuticals’ agreement to acquire Gameto, a cell-engineering company reimagining IVF, in a deal worth up to $1.38 billion.

Top 10 Deals of 2026: Sun Pharma to Acquire Organon for $11.75B

Every year, Amboy Street highlights the top 10 transactions in women’s health. This year’s series starts with one of the largest women’s health mergers in history.

Top 10 Deals of 2026: ŌURA to Acquire Counsel Health for $625M

Every year, Amboy Street highlights the top 10 transactions in women’s health. The next deal in this year’s series is ŌURA’s agreement to acquire Counsel Health, an AI-native primary care company, for $625 million in cash.

Top 10 Deals of 2026: Ferring to Acquire Gameto for up to $1.38B

Every year, Amboy Street highlights the top 10 transactions in women’s health. The splashy news of the week, and the next blog in our series, is Ferring Pharmaceuticals’ agreement to acquire Gameto, a cell-engineering company reimagining IVF, in a deal worth up to $1.38 billion.

Fast track our industry.
Get in touch today.